At SIINOVIA, we believe that effective medicines should integrate seamlessly into everyday care. Our latest research model balances clinical efficacy with patient-centric design, optimizing bioavailability and convenience to contribute to significantly better health outcomes.

The Federal Institute for Drugs and Medical Devices delivers positive feedback on Siinovia’s development pipeline formulations.

A major step forward in patient-centred formulations, expanding access to customizable melatonin dosage strengths.

Expanding our internal manufacturing capabilities to guarantee consistent and reliable UK wholesale supply chains.